Development of antivirulence compounds: A biochemical review

Chemical Biology and Drug Design

Volumn 85, Issue 1, 2015, Pages 43-55

  Zambelloni, Riccardo ^a   Marquez, Rudi ^b   Roe, Andrew J ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

biological screening; chemical biology; structure based drug design; therapeutic target

Indexed keywords

1 METHYLMOCIMYCIN; ANTIBIOTIC AGENT; CARBOHYDRATE DERIVATIVE; ELONGATION FACTOR TU; GUANIDINE DERIVATIVE; HYDROXAMIC ACID; IRON; NATURAL PRODUCT; PICOLINIC ACID; SULFONAMIDE; ANTIINFECTIVE AGENT;

ARTICLE; AUTOPHOSPHORYLATION; BACILLUS ANTHRACIS; BACTERIAL GROWTH; BACTERIAL OUTER MEMBRANE; BACTERIAL VIRULENCE; CHEMICAL STRUCTURE; CITROBACTER RODENTIUM; CYCLIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION; GRAM NEGATIVE BACTERIUM; HIGH THROUGHPUT SCREENING; IC50; IN VIVO STUDY; KNOEVENAGEL CONDENSATION; LETHAL GENE; MACROPHAGE; MAMMAL CELL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; QUORUM SENSING; RECEPTOR BINDING; STREPTOMYCES; STREPTOMYCES GOLDINIENSIS; STRUCTURE ACTIVITY RELATION; TANDEM MASS SPECTROMETRY; TYPE III SECRETION SYSTEM; VIBRIO CHOLERAE; YERSINIA PESTIS; DRUG DESIGN; DRUG DEVELOPMENT; DRUG RESISTANCE; HUMAN; TRENDS;

BACTERIA (MICROORGANISMS); NEGIBACTERIA;

ANTI-BACTERIAL AGENTS; DRUG DESIGN; DRUG DISCOVERY; DRUG RESISTANCE; HUMANS; QUORUM SENSING;

EID: 84918814054     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12430     Document Type: Article

References (110)

1. Rasko D.A., Sperandio V., (2010) Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev; 9: 117-128.
2. Staskawicz B.J., Mudgett M.B., Dangl J.L., Galan J.E., (2001) Common and contrasting themes of plant and animal diseases. Science; 292: 2285-2289.
3. Werner G., Strommenger B., Witte W., (2008) Acquired vancomycin resistance in clinically relevant pathogens. Future Microbiol; 3: 547-562.
4. Hanson M.R., Chung C.L., (2009) Antibiotic selection for MRSA: case presentations and review of the literature. J Drugs Dermatol; 8: 281-286.
5. Rasko D.A., Moreira C.G., Li de R., Reading N.C., Ritchie J.M., Waldor M.K., Williams N., Taussig R., Wei S., Roth M., Hughes D.T., Huntley J.F., Fina M.W., Falck J.R., Sperandio V., (2008) Targeting QseC signaling and virulence for antibiotic development. Science; 321: 1078-1080.
6. Cornelis G.R., (2006) The type III secretion injectisome. Nat Rev Microbiol; 4: 811-825.
7. Alfano J.R., Collmer A., (2004) Type III secretion system effector proteins: double agents in bacterial disease and plant defense. Annu Rev Phytopathol; 42: 385-414.
8. Cornelis G.R., Wolf-Watz H., (1997) The Yersinia Yop virulon: a bacterial system for subverting eukaryotic cells. Mol Microbiol; 23: 861-867.
9. Galan J.E., Collmer A., (1999) Type III secretion machines: bacterial devices for protein delivery into host cells. Science; 284: 1322-1328.
10. Cornelis G.R., Van Gijsegem F., (2000) Assembly and function of type III secretory systems. Annu Rev Microbiol; 54: 735-774.
11. Linington M.G., Robertson M., Gauthier A., Finlay B.B., MacMillan J.B., Molinski T.F., van Soest R., Andersen R.J., (2002) Caminoside A, an Antimicrobial Glycolipid Isolated from the Marine Sponge Caminus sphaeroconia. Org Lett; 4: 4089-4092.
12. Zhang Z., Zong C., Song G., Lu G., Chun Y., Wang P., Ding N., Li Y., (2010) Total synthesis of caminoside B, a novel antimicrobial glycolipid isolated from the marine sponge Caminus sphaeroconia. Carbohydr Res; 345: 750-760.
13. Parmeggiani A., Swart G., (1985) Mechanism of action of kirromycin-like antibiotics. Annu Rev Microbiol; 39: 557-577.
14. Kimura K., Iwatsuki M., Nagai T., Matsumoto A., Takahashi Y., Shiomi K., Omura S., Abe A., (2011) A small-molecule inhibitor of the bacterial type III secretion system protects against in vivo infection with Citrobacter rodentium. J Antibiot (Tokyo); 64: 197-203.
15. Iwatsuki M., Uchida R., Yoshijima H., Ui H., Shiomi K., Kim Y., Hirose T., Sunazuka T., Abe A., Tomoda H., Omura S., (2008) Guadinomines, Type III secretion system inhibitors, produced by Streptomyces sp. K01-0509. I: taxonomy, fermentation, isolation and biological properties. J Antibiot (Tokyo); 61: 222-229.
16. Li J., Lv C., Sun W., Li Z., Han X., Li Y., Shen Y., (2013) Cytosporone B, an inhibitor of the type III secretion system of Salmonella enterica serovar Typhimurium. Antimicrob Agents Chemother; 57: 2191-2198.
17. Liu J.Y., Ye Y.H., Wang L., Shi D.H., Tan R.X., (2005) New resveratrol oligomers from the stem bark of Hopea hainanensis. Helv Chim Acta; 88: 2910-2917.
18. Zetterstrom C.E., Hasselgren J., Salin O., Davis R.A., Quinn R., Sundin C., Elofsson M., (2013) The resveratrol tetramer (-)-hopeaphenol inhibits type III secretion in the gram-negative pathogens Yersinia pseudotuberculosis and Pseudomonas aeruginosa. PLoS ONE; 8: 1-12.
19. Duncan M.C., Wong W.R., Dupzyc A.J., Bray W.M., Linington R.G., Auerbuch V., (2014) An NF-κB-based high-throughput screen identifies piericidins as inhibitors of the Yersinia pseudotuberculosis type III secretion system. Antimicrob Agents Chemother; 58: 1118-1126.
20. Pan N.J., Brady M.J., Leong J.M., Goguen J.D., (2008) Targeting type III secretion in Yersinia pestis. Antimicrob Agents Chemother; 53: 385-392.
21. Jessen D.L., Bradley D.S., Nilles M.L., (2014) A type III secretion system inhibitor targets YopD while revealing differential regulation of secretion in calcium-blind mutants of Yersinia pestis. Antimicrob Agents Chemother; 58: 839-850.
22. Felise H.B., Nguyen H.V., Pfuetzner R.A., Barry K.C., Jackson S.R., Blanc M.P., Bronstein P.A., Kline T., Miller S.I., (2008) An inhibitor of gram-negative bacterial virulence protein secretion. Cell Host Microbe; 4: 325-336.
23. Kline T., Felise H.B., Barry K.C., Jackson S.R., Nguyen H.V., Miller S.I., (2009) Substituted 2-imino-5-arylidenethiazolidin-4-one inhibitors of bacterial type III secretion. J Med Chem; 51: 7065-7074.
24. Kauppi A.M., Nordfelth R., Uvell H., Wolf-Waltz H., Elofsson M., (2003) Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem Biol; 10: 241-249.
25. Wolf K., Betts H.J., Chellas-Gery B., Hower S., Linton C.N., Fields K.A., (2006) Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle. Mol Microbiol; 61: 1543-1555.
26. Muschiol S., Bailey L., Gylfe A., Sundin C., Hultenby K., Bergstrom S., Elofsson M., Wolf-Waltz H., Normark S., Henriques-Normark B., (2006) A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc Natl Acad Sci USA; 103: 14566-14571.
27. Hudson D.L., Layton A.N., Field T.R., Bowen A.J., Wolf-Waltz H., Elofsson M., Stevens M.P., Gaylov E.E., (2007) Inhibition of type III secretion in Salmonella enterica serovar Typhimurium by small-molecule inhibitors. Antimicrob Agents Chemother; 51: 2631-2635.
28. Negrea A., Bjur E., Ygberg S.E., Elofsson M., Wolf-Waltz H., Rhen M., (2007) Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica serovar typhimurium. Antimicrob Agents Chemother; 51: 2867-2876.
29. Veenendaal A.K.J., Sundin C., Blocker A.J., (2009) Small-molecule type III secretion system inhibitors block assembly of the Shigella type III secreton. J Bacteriol; 191: 563-570.
30. Tree J.J., Wang D., McInally C., Mahajan A., Layton A., Houghton I., Elofsson M., Stevens M.P., Gally D.L., Roe A.J., (2009) Characterization of the effects of salicylidene acylhydrazide compounds on type III secretion in Escherichia coli O157:H7. Infect Immun; 77: 4209-4220.
31. Martinez-Argudo I., Veenendaal A.K.J., Liu X., Roehrich A.D., Ronessen M.C., Franzoni G., van Rietschoten K.N., Morimoto Y.V., Saijo-Hamano Y., Avison M.B., Studholme D.J., Namba K., Minamino T., Blocker A.J., (2013) Isolation of Salmonella mutants resistant to the inhibitory effect of Salicylidene acylhydrazides on flagella-mediated motility. PLoS ONE; 8: e52179.
32. Slepenkin A., Enquist P.A., Hagglund U., De la Maza L.M., Elofsson M., Peterson E.M., (2007) Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron. Infect Immun; 75: 3478-3489.
33. Layton A.L., Hudson D.L., Thompson A., Hinton J.C.D., Stevens J.M., Gaylov E.E., Stevens M.P., (2010) Salicylidene acylhydrazide-mediated inhibition of type III secretion system-1 in Salmonella enterica serovar Typhimurium is associated with iron restriction and can be reversed by free iron. FEMS Microbiol Lett; 302: 114-122.
34. Wang D., Zetterstrom C.E., Gabrielsen M., Beckham K.S.H., Tree J.J., MacDonald S.E., Byron O., et al,. (2011) Identification of bacterial target proteins for the salicylidene acylhydrazide class of virulence-blocking compounds. J Biol Chem; 286: 29922-29931.
35. Gabrielsen M., Zetterstrom C.E., Wang D., Beckham K.H.S., Elofsson M., Isaacs N.W., Roe A.J., (2011) Expression, purification, crystallization and initial X-ray diffraction analysis of thiol peroxidase from Yersinia pseudotuberculosis. Acta Cryst; F66: 1606-1609.
36. Baker L.M., Poole L.B., (2003) Catalytic mechanism of thiol peroxidase from Escherichia coli. Sulfenic acid formation and overoxidation of essential CYS61. J Biol Chem; 278: 9203-9211.
37. Patridge E.V., Ferry J.G., (2006) WrbA from Escherichia coli and Archaeoglobus fulgidus is an NAD(P)H:quinone oxidoreductase. J Bacteriol; 188: 3498-3506.
38. Gabrielsen M., Beckham K.H.S., Feher V.A., Zetterstrom C.E., Wang D., Muller S., Elofsson E., Amaro R.E., Byron O., Roe A.J., (2012) Structural characterisation of Tpx from Yersinia pseudotuberculosis reveals insights into the binding of salicylidene acylhydrazide compounds. PLoS ONE; 7: e32217.
39. Gabrielsen M., Beckham K.H.S., Cogdell R.J., Byron O., Roe A.J., (2012) FolX from Pseudomonas aeruginosa is octameric in both crystal and solution. FEBS Lett; 586: 1160-1165.
40. Beckham K.H.S., Byron O., Roe A.J., Gabrielsen M., (2012) The structure of an orthorhombic crystal form of a 'forced reduced' thiol peroxidase reveals lattice formation aided by the presence of the affinity tag. Acta Cryst; F66: 522-526.
41. Clarke M.B., Hughes D.T., Zhu C., Boedeker C.E., Sperandio V., (2006) The QseC sensor kinase: a bacterial adrenergic receptor. Proc Natl Acad Sci USA; 103: 10420.
42. Hughes D.T., Sperandio V., (2008) Inter-kingdom signalling: communication between bacteria and their hosts. Nat Rev Microbiol; 6: 111.
43. Sperandio V., Torres A.G., Jarvis B., Nataro J.P., Kaper J.B., (2003) Bacteria-host communication: the language of hormones. Proc Natl Acad Sci USA; 100: 8951.
44. Clarke M.B., Sperandio V., (2005) Transcriptional regulation of flhDC by QseBC and sigma (FliA) in enterohaemorrhagic Escherichia coli. Mol Microbiol; 57: 1734-1749.
45. Hughes D.T., Clarke M.B., Yamamoto K., Rasko D.A., Sperandio V., (2009) The QseC adrenergic signaling cascade in Enterohemorrhagic E. coli (EHEC). PLoS Pathog; 5: e1000553.
46. Lyte M., Arulanandam A.M., Frank C.D., (1996) Production of Shiga-like toxins by Escherichia coli O157:H7 can be influenced by the neuroendocrine hormone norepinephrine. J Lab Clin Med; 128: 392-398.
47. Lyte M., Erickson A.K., Arulanandam B.P., Frank C.D., Crawford M.A., Francis D.H., (1997) Norepinephrine-induced expression of the K99 pilus adhesin of enterotoxigenic Escherichia coli. Biochem Biophys Res Commun; 232: 682-686.
48. Rasko D.A., Moreira C.G., Li D.R., Reading N.C., Ritchie J.M., Waldor M.K., Williams N., Taussig R., Wei S., Roth M., Hughes D.T., Huntley J.F., Fina M.W., Falck J.R., Sperandio V., (2008) Targeting QseC signaling and virulence for antibiotic development. Science; 321: 1078-1080.
49. Bearson B.L., Bearson S.M., (2008) The role of the QseC quorum-sensing sensor kinase in colonization and norepinephrine-enhanced motility of Salmonella enterica serovar Typhimurium. Microb Pathog; 44: 271.
50. Weiss D.S., Brotcke A., Henry T., Margolis J.J., Chan K., Monack D.M., (2007) In vivo negative selection screen identifies genes required for Francisella virulence. Proc Natl Acad Sci USA; 104: 6037.
51. Sperandio V., Falck J.R., Steweart D.R., (2009) Methods of inhibiting bacterial virulence and compounds relating thereto. PCT Int Appl; A2: WO2009088549.
52. Reidl J., Klose K.E., (2002) Vibrio cholerae and cholera: out of the water and into the host. FEMS Microbiol Rev; 26: 125-139.
53. Waldor M.K., Mekalonos J.J., (1996) Enteric Infections and Immunity, Paradise LJ Ed. New York: Plenum; p. 37-55.
54. Shakhnovich E.A., Hung D.T., Pierson E., Lee K., Mekalonos J.J., (2007) Virstatin inhibits dimerization of the transcriptional activator ToxT. Proc Natl Acad Sci USA; 104: 2372-2377.
55. Higgins D.E., Nazareno E., DiRita V.J., (1992) The virulence gene activator ToxT from Vibrio cholerae is a member of the AraC family of transcriptional activators. J Bacteriol; 174: 6974-6980.
56. Hulbert R.R., Taylor R.K., (2002) Mechanism of ToxT-dependent transcriptional activation at the Vibrio cholerae tcpA promoter. J Bacteriol; 184: 5533-5544.
57. Gallegos M.T., Schleif R., Bairoch A., Hofmann K., Ramos J.L., (1997) Arac/XylS family of transcriptional regulators. Microbiol Mol Biol Rev; 61: 393-410.
58. Hung D.T., Shakhnovich E.A., Pierson E., Mekalonos J.J., (2005) Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization. Science; 310: 670.
59. Adam W., Beck A.K., Pichota A., Saha-Moller C.R., Seebach D., Vogl N., Zhang R., (2003) Control of enantioselectivity through a hydrogen-bonded template in the vanadium(V)-catalyzed epoxidation of allylic alcohols by optically active hydroperoxides. Tetrahedron Asymmetry; 14: 1355-1361.
60. Friedlander A.M., (2000) Anthrax: clinical features, pathogenesis, and potential biological warfare threat. Curr Clin Top Infect Dis; 20: 335-349.
61. Dixon T.C., Fadl A.A., Koehler T.M., Swanson J.A., Hanna P.C., (2000) Early Bacillus anthracis-macrophage interactions: intracellular survival survival and escape. Cell Microbiol; 2: 453-463.
62. Hanna P.C., Ireland J.A., (1999) Understanding Bacillus anthracis pathogenesis. Trends Microbiol; 7: 180-182.
63. Dixon T.C., Meselsom M., Guillemin J., Hanna P.C., (1999) Anthrax. New Eng J Med; 341: 815.
64. Collier R.J., Young J.A., (2003) Anthrax toxin. Annu Rev Cell Dev Biol; 19: 45.
65. Bradley K.A., Mogridge J., Mourez M., Collier R.J., Young J.A., (2001) Identification of the cellular receptor for anthrax toxin. Nature; 414: 225-229.
66. Scobie H.M., Rainey G.J., Bradley K.A., Young J.A., (2003) Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad Sci USA; 100: 5170-5174.
67. Pemental R.L., Christensen K.A., Krantz B.A., Collier R.J., (2004) Anthrax toxin complexes: heptameric protective antigen can bind lethal factor and edema factor simultaneously. Biochem Biophys Res Commu; 322: 258.
68. Duesbery N.S., Webb C.P., Leppla S.H., Gordon V.M., Kimpel K.R., Copeland T.D., Ahn N.G., Oskarsson M.K., Fukasawa K., Paull K.D., Woude G.F., (1998) Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science; 280: 734.
69. Pennifer A.D., Wong T.Y., Schwarzenbacher R., Renatus M., Petosa C., Blenkowska J., Lacy D.B., Collier R.J., Park S., Leppla S.H., Hanna P., Liddington R.C., (2001) Crystal structure of the anthrax lethal factor. Nature; 414: 229.
70. Pezard C., Berche P., Mock M., (1991) Contribution of individual toxin components to virulence of Bacillus anthracis. Infect Immun; 59: 3472.
71. Cummings R.T., Salowe S.P., Cunningham B.R., Wiltsie J., Park Y.W., Sonatore L.M., Wisneiwski D., Douglas C.M., Hermes J.D., Scolnick E., (2002) A peptide-based fluorescence resonance energy transfer assay for Bacillus anthracis lethal factor protease. Proc Natl Acad Sci USA; 10: 6603.
72. Tang G., Leppla S., (1999) Proteasome activity is required for anthrax lethal toxin to kill macrophages. Infect Immun; 67: 3055.
73. Xiong Y., Wiltsie J., Woods A., Guo J., Pivnichny J.V., Tang W., Bansal A., et al,. (2006) The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection. Bioorg Med Chem Lett; 16: 964-968.
74. Schoop W.L., Xiong Y., Wiltsie J., Woods A., Guo J., Pivnichny J.V., Felcetto T., et al,. (2005) Anthrax lethal factor inhibition. Proc Natl Acad Sci USA; 102: 7958-7963.
75. Kim S., Jiao G.S., Moayeri M., Crown D., Cregar-Hernandez L., McKasson L., Margosiak S.A., Leppla S.H., Johnson A.T., (2011) Antidotes to anthrax lethal factor intoxication. Part 2: structural modifications leading to improved in vivo efficacy. Bioorg Med Chem Lett; 21: 2030-2033.
76. Agrawal A., de Oliveira C.A., Cheng Y., Jacobsen J.A., McCammon J.A., Cohen S.N., (1063) Thioamide hydroxypyrothiones supersede amide hydroxypyrothiones in potency against anthrax lethal factor. J Med Chem; 2009: 52.
77. Min D.H., Tang W.J., Mrksich M., (2004) Chemical screening by mass spectrometry to identify inhibitors of anthrax lethal factor. Nat Biotechnol; 22: 717.
78. Chiu T.L., Solberg J., Patil S., Geders T.W., Zhang X., Rangarajan S., Francis R., Finzel B.C., Walters M.A., Hook D.J., Amin E.A., (2009) Identification of novel non-hydroxamate anthrax toxin lethal factor inhibitors by topomeric searching, docking and scoring, and in vitro screening. J Chem Inf Model; 49: 2726.
79. Tang J., Park J.G., Millard C.B., Schmidt J.J., Pang Y.P., (2007) Computer-aided lead optimization: improved small-molecule inhibitor of the zinc endopeptidase of botulinum neurotoxin serotype A. PLoS ONE; 2: e761.
80. Sauer F.G., Remaut H., Hultgren S.J., Waksman G., (2004) Fiber assembly by the chaperone-usher pathway. Biochem Biophys Acta; 1694: 259-267.
81. Hung D.L., Knight S.D., Woods R.M., Pinkner J.S., Hultgren S.J., (1996) Molecular basis of two subfamilies of immunoglobulin-like chaperones. EMBO J; 15: 3792-3805.
82. Roberts J.A., Marklund B.I., Ilver D., Haslam D., Kaack M.B., Baskin G., Louis M., Mollby R., Winberg J., Normark S., (1994) The Gal(alpha 1-4)Gal-specific tip adhesin of Escherichia coli P-fimbriae is needed for pyelonephritis to occur in the normal urinary tract. Proc Natl Acad Sci USA; 91: 11889-11893.
83. Dodson K.W., Pinkner J.S., Rose T., Magnusson G., Hultgren S.J., Waksman G., (2001) Structural basis of the interaction of the pyelonephritic E. coli adhesin to its human kidney receptor. Cell; 105: 733-743.
84. Anderson G.G., Palermo J.J., Shilling J.D., Roth R., Heuser J., Hultgren S.J., (2003) Intracellular bacterial biofilm-like pods in urinary tract infections. Science; 301: 105-107.
85. Justice S.S., Hung C., Theriot J.A., Fletcher D.A., Anderson G.G., Footer M.J., Hultgren S.J., (2004) Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc Natl Acad Sci USA; 101: 1333-1338.
86. Bann J.G., Pinkner J.S., Frieden C., Hultgren S.J., (2004) Catalysis of protein folding by chaperones in pathogenic bacteria. Proc Natl Acad Sci USA; 101: 17389-17393.
87. Vetsch M., Pourger C., Spirig T., Grauschopf U., Weber-Ban E.U., Glockshuber R., (2004) Pilus chaperones represent a new type of protein-folding catalyst. Nature; 431: 329-332.
88. Dodson K.W., Jacobdubuisson F., Striker R.T., Hultgren S.J., (1993) Outer-membrane PapC molecular usher discriminately recognizes periplasmic chaperone-pilus subunit complexes. Proc Natl Acad Sci USA; 90: 3670-3674.
89. Thanassi D.G., Saulino E.T., Lombardo R.J., Roth R., Heuser J., Hultgren S.J., (1998) The PapC usher forms an oligomeric channel: implications for pilus biogenesis across the outer membrane. Proc Natl Acad Sci USA; 95: 3146-3151.
90. Holmgren A., Branden C.I., (1989) Crystal structure of chaperone protein PapD reveals an immunoglobulin fold. Nature; 342: 248-251.
91. Choudhury D., Thompson A., Stojanoff V., Langermann S., Pinkner J., Hultgren S.J., Knight S.D., (1999) X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli. Science; 285: 1061-1066.
92. Sauer F.G., Futterer K., Pinkner J.S., Dodson K.W., Hultgren S.J., Waksman G., (1999) Structural basis of chaperone function and pilus biogenesis. Science; 285: 1058-1061.
93. Sauer F.G., Pinkner J.S., Waksman G., Hultgren S.J., (2002) Chaperone priming of pilus subunits facilitates a topological transition that drives fiber formation. Cell; 111: 543-551.
94. Nishiyama M., Horst R., Eidam O., Herrmann T., Ignatov O., Vetsch M., Bettendorff P., Jelerasov I., Grutter M.G., Wuthrich K., Glockshuber R., Capitani G., (2005) Structural basis of chaperone-subunit complex recognition by the type 1 pilus assembly platform FimD. EMBO J; 24: 2075-2086.
95. Ng T.W., Akman L., Osisami M., Thanassi D.G., (2004) The usher N terminus is the initial targeting site for chaperone-subunit complexes and participates in subsequent pilus biogenesis events. J Bacteriol; 186: 5321-5331.
96. Barnhart M.M., Pinkner J.S., Soto G.E., Sauer F.G., Langermann S., Waksman G., Frieden C., Hultgren S.J., (2000) PapD-like chaperones provide the missing information for folding of pilin proteins. Porc Natl Acad Sci USA; 97: 7709-7714.
97. Remaut H., Rose J., Hannan T.J., Hultgren S.J., Radford S.E., Ashcroft A.E., Waksman G., (2006) Donor-strand exchange in chaperone-assisted pilus assembly proceeds through a concerted beta strand displacement mechanism. Mol Cell; 22: 831-842.
98. Zavialov A.V., Berglund J., Pudney A.F., Fooks L.J., Ibrahim T.M., McIntyre S., Knight S.D., (2003) Structure and biogenesis of the capsular F1 antigen from Yersinia pestis: preserved folding energy drives fiber formation. Cell; 113: 587-596.
99. Kuehn M.J., Ogg D.J., Kihlberg J., Slonim L.R., Flemmer K., Bergfors T., Hultgren S.J., (1993) Structural basis of pilus subunit recognition by the PapD chaperone. Science; 262: 1234-1241.
100. Svensson A., Larsson A., Emtenas H., Hedenstrom M., Fex T., Hultgren S.J., Pinkner J.S., Almqvist F., Kihlberg J., (2001) Design and evaluation of pilicides: potential novel antibacterial agents directed against uropathogenic Escherichia coli. ChemBioChem; 12: 915-918.
101. Earp R.L., Dessy R.E., (1998) Chem Anal; 148: 99-164.
102. Pinkner J.S., Remaut H., Buelens F., Miller E., Aberg V., Pemberton N., Hedenstrom M., Larsson A., Seed P., Waksman G., Hultgren S.J., Almqvist F., (2006) Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc Natl Acad Sci USA; 103: 17897-17902.
103. Pemberton N., Arbeg V., Almstedt H., Westermark A., Almqvist F., (2004) Microwave-assisted synthesis of highly substituted aminomethylated 2-pyridones. J Org Chem; 69: 7830-7835.
104. Chorell E., Pinkner J.S., Phan G., Edvinsson S., Buelens F., Remaut H., Waksman G., Hultgren S.J., Almqvist F., (2010) Design and synthesis of C-2 substituted thiazolo and dihydrothiazolo ring-fused 2-pyridones: pilicides with increased antivirulence activity. J Med Chem; 53: 5690-5695.
105. Chorell E., Das P., Almqvist F., (2007) Diverse functionalization of thiazolo ring-fused 2-pyridones. J Org Chem; 72: 4917-4924.
106. Krishnan K.S., Bengtsson C., Good J.A.D., Mirkhanov S., Chorell E., Johansson L.B.A., Almqvist F., (2013) Synthesis of fluorescent ring-fused 2-pyridone peptidomimetics. J Org Chem; 78: 12207-12213.
107. Smith M.A., Coincon M., Paschos A., Jolicoeur B., Lavallee P., Sygusch J., Baron C., (2012) Identification of the binding site of Brucella VirB8 interaction inhibitors. Chem Biol; 19: 1041-1048.
108. Miller M.B., Bassler B.L., (2001) Quorum sensing in bacteria. Annu Rev Microbiol; 55: 165-199.
109. Lazdunski A., Ventre I., Sturgis J.N., (2004) Regulatory circuits and communication in Gram-negative bacteria. Nat Rev Microbiol; 2: 581-592.
110. Winzer K., Hardie K.R., Williams P., (2002) Bacterial cell-to-cell communication: sorry, can't talk now-gone to lunch! Curr Opin Microbiol; 5: 216-222.